Selling, General, and Administrative Costs: Bio-Techne Corporation vs Sarepta Therapeutics, Inc.

A Comparative Analysis of SG&A Expenses in the Biotech Sector

In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Bio-Techne Corporation and Sarepta Therapeutics, Inc., from 2014 to 2023.

Bio-Techne Corporation has shown a consistent upward trend in SG&A expenses, starting at approximately $60 million in 2014 and reaching nearly $397 million by 2023. This represents a growth of over 560% in a decade, reflecting the company's expansion and increased operational activities.

Sarepta Therapeutics, Inc. also experienced significant growth, with SG&A expenses rising from around $49 million in 2014 to about $482 million in 2023, marking an impressive increase of nearly 880%. However, data for 2024 is currently unavailable, indicating potential future updates.

These trends highlight the dynamic nature of the biotech sector, where strategic investments in administrative capabilities are pivotal for sustained growth.